Early assessment of endocan level as a predictor of remission status in acute leukemia patients

Rasha Magdy M Said; Tamer M. Ahmed; Rana Z. Abbas; Heba S. Agamy; Raed A. Shamkh; Basma S. M. Ali

doi:10.2478/fco-2024-0019

.blurhash-client-img { display: none !important; }

Early assessment of endocan level as a predictor of remission status in acute leukemia patients

Forum of Clinical Oncology

AHEAD OF PRINT

By: Rasha Magdy M Said, Tamer M. Ahmed, Rana Z. Abbas, Heba S. Agamy, Raed A. Shamkh and Basma S. M. Ali

Open Access

|Mar 2026

Figures & Tables

Comparison between initial endocan level and post-induction endocan level among the examined patients.

Correlation between initial endocan level and LDH level among the studied patients.

The correlation between initial endocan and initial bone marrow blasts percentage among the studied patients.

Comparison between initial endocan level and post-induction endocan_

		Initial	Post-induction	Test value	P-value	Sig.
Endocan	Median (IQR)	1950 (1637–2400)	385 (234–500)	−5.481≠	0.000***	HS***
Endocan	Range	1100–2400	150–1617	−5.481≠	0.000***	HS***

Outcome of the examined patients_

		Total no. = 45
Mortality	Alive	86.7% (n = 39)
Mortality	Died	13.3% (n = 6)
OS (6 months)	Mean ± SD	3.87 ± 1.73
OS (6 months)	Range	1–6
Remission status	Responders	88.9% (n = 40)
Remission status	Non-responders	11.1% (n = 5)
PFS (6 months)	Mean ± SD	3.44 ± 1.73
PFS (6 months)	Range	1–6

Comparison of endocan levels in responders and non-responder patients_

		Remission status		Test value	P-value	Sig.
		Responders	Non-responders

		No. = 40	No. = 5
Initial endocan	Median (IQR)	1915 (1582–2377.5)	2400 (2300–2400)	−1.841≠	0.066*	NS
Initial endocan	Range	1100–2400	1885–2400	−1.841≠	0.066*	NS

Post-induction endocan	Median (IQR)	342 (231.5–500)	496 (404–500)	−1.300≠	0.193*	NS
Post-induction endocan	Range	150–1617	302–615	−1.300≠	0.193*	NS

Patient characteristics and disease categorization of analyzed patients_

		Total no. = 45
Age	Mean ± SD	31.38 ± 10.36
Age	Range	14–56
Gender	Female	55.6% (n = 25)
Gender	Male	44.4% (n = 20)
Comorbidities	Negative	68.9% (n = 31)
Comorbidities	Positive	31.1% (n = 14)
Diagnosis	AML	44.4% (n = 20)
Diagnosis	ALL	51.1% (n = 23)
FAB (AML)	Mixed phenotypic	4.4% (n = 2)
	M1	25% (n = 5)
	M2	20% (n = 4)
	M3	20% (n = 4)
	M4	20% (n = 4)
	M5	15% (n = 3)
(ALL)	B ALL	47.8% (n = 11)
(ALL)	T ALL	52.2% (n = 12)

Endocan levels in responders versus non-responders AML and ALL patients_

AML		Remission status		Test value	P-value	Sig.
		Responders	Non-responders

		No. = 18	No. = 2
Initial endocan	Median (IQR)	1898 (1566–2356)	2400 (2400–2400)	1.905^≠	0.057**	NS
Initial endocan	Range	1100–2400	2400–2400	1.905^≠	0.057**	NS
Post-induction endocan	Median (IQR)	388 (320–492)	399 (302–496)	0.126^≠	0.900*	NS
Post-induction endocan	Range	202–900	302–496	0.126^≠	0.900*	NS

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/fco-2024-0019 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Submitted on: Aug 2, 2025

Accepted on: Nov 4, 2025

Published on: Mar 24, 2026

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

Related subjects:

Haematology, oncology

© 2026 Rasha Magdy M Said, Tamer M. Ahmed, Rana Z. Abbas, Heba S. Agamy, Raed A. Shamkh, Basma S. M. Ali, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

AHEAD OF PRINT

Early assessment of endocan level as a predictor of remission status in acute leukemia patients

Figures & Tables

Fig. (a):

Fig. (b):

Fig. (c):

Comparison between initial endocan level and post-induction endocan_

Outcome of the examined patients_

Comparison of endocan levels in responders and non-responder patients_

Patient characteristics and disease categorization of analyzed patients_

Endocan levels in responders versus non-responders AML and ALL patients_

Paradigm

My account